School of Medicine


Showing 1-10 of 11 Results

  • Michelle Madore, Ph.D.

    Michelle Madore, Ph.D.

    Staff, Psych/Major Laboratories and Clinical & Translational Neurosciences Incubator
    Clinical Assistant Professor (Affiliated), Psych/Public Mental Health & Population Sciences

    BioDr. Madore is multiracial, Filipina woman working as a Clinical Neuropsychologist at VA Palo Alto Healthcare System (VAPAHCS) in the Mental Illness Research, Education and Clinical Center (MIRECC).  Here she serves as the Director of the National Clinical Transcranial Magnetic Stimulation (TMS) Program whose mission is to: 1) increase the availability of Transcranial Magnetic Stimulation (TMS) for treatment-resistant depression in Veterans and (2) gain a greater understanding of the treatment efficacy of TMS in our complex Veteran population. She is also the Co-Director of the Sierra Pacific MIRECC Advanced Fellowship at VAPAHCS. Dr. Madore is the site PI on two multi-site funded studies looking at neuroimaging biomarkers of treatment response to TMS in treatment-resistant depression. Dr. Madore is also a Clinical Assistant Professor (Affiliated) at Stanford University School of Medicine’s Department in Psychiatry and Behavioral Sciences.

    She received her Ph.D. in clinical psychology from the University of Cincinnati, where she received specialized training in neuropsychology. Dr. Madore completed her pre-doctoral internship at the VA Palo Alto Health Care System (VAPAHCS).  She has completed postdoctoral training focused on clinical neuropsychology and neurorehabilitation research at VA Martinez, San Francisco VA Medical Center and VAPAHCS.

    Dr. Madore is involved in several professional organizations and serves in several leadership positions. She is the Society of Clinical Neuropsychology Secretary and is the Incoming Editor for the Asian American Journal of Psychology.

  • Mark McGovern

    Mark McGovern

    Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)

    BioDr. Mark McGovern is a Professor in the Department of Psychiatry & Behavioral Sciences and, by courtesy, the Department of Medicine at Stanford University School of Medicine.

    Most people who need health care do not receive it. And of those who do, wide variation exists in the quality of the care they receive. Gaps in health care access and quality are worse for certain groups, such as underrepresented minorities and persons living in low-resourced urban and rural areas, and/or in poverty. Enormous disparities exist in health care systems, both private and public. Dr. McGovern is a leader in using rigorous methods of dissemination and implementation (D&I) science to close these gaps in equitable health care delivery.

    His mission is to get the best health care possible to the people who need it the most.

    Dr. McGovern's primary focus is the implementation and sustainment of evidence-based interventions and guideline adherent care in public and private health care systems and organizations. Within the hub of the Center for Dissemination and Implementation (CDI) which he directs, Dr. McGovern is the Principal Investigator (PI) and leads three national dissemination and implementation (D&I) centers: The Center for Dissemination and Implementation At Stanford (C-DIAS); The Research Adoption Support Center (RASC); and, the Mental Health Technology Transfer Center Network Coordinating Center (MHTTC). The 3 centers are federally-funded, respectively by the National Institute on Drug Abuse (P50DA05402), the National Institutes of Health Healing Addiction Long Term (HEAL) initiative (U2CDA057717), and the US Department of Health and Human Services Substance Use and Mental Health Services Administration (H79SM081726). Dr. McGovern is also the PI on a multi-site adaptive implementation trial across a state system of care, which aims to integrate addiction medications for persons with opioid use disorder who are receiving services in specialty or primary care organizations (R01DA052975). In addition, he conducts D&I research and practice projects in federally-qualified health centers (FQHCs) across the State of California, in the Stanford Division of Primary Care and Population Health, and in specialty addiction and mental health treatment organizations nationwide. He leads, facilitates and/or actively engages networks advancing D&I science in health, including the NIDA Clinical Trials Network Translation & Implementation Special Interest Group, the NIDA Clinical Trials Western States Node Translation & Implementation Workgroup, the Stanford University Network for Dissemination & Implementation Research (SUNDIR), the VA Palo Alto HSR&D Center for Innovation to Implementation, and the Stanford Medicine Center for Improvement. He is on the Core Faculty of the National Institute of Mental Health Implementation Research Institute at the Washington University in St. Louis. Dr. McGovern is a collaborator on multiple projects as a co-investigator, consultant, or advisory board member. He is a mentor to numerous individuals across the country and at Stanford, from university undergraduates to mid-career faculty and clinical administrators at academic institutions and health care systems nationwide.

  • Martin Stefan Mumenthaler

    Martin Stefan Mumenthaler

    Adjunct Professor, Psych/Public Mental Health & Population Sciences

    BioMartin Mumenthaler has a PharmD and a PhD in psychopharmacology from the University of Bern, Switzerland. He holds an appointment as Adjunct Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine where he has been conducting research programs in addiction medicine and psychopharmacology, and teaching and mentoring medical students and residents on a voluntary basis.
    Dr. Mumenthaler has also been working in various full-time positions in the pharmaceutical industry as Director in Clinical Development as well as in Medical Affairs, and as a consultant for early-stage pharma- and biotech companies providing advice on designing and conducting clinical trials, and analyzing and interpreting study results, mainly in the field of addiction medicine and pain.
    His academic research has focused on the effects of psychoactive drugs on human performance, Aerospace Medicine, Alzheimer’s disease, and addiction medicine, and in these areas he has presented his results internationally and published over twenty-five peer-reviewed scientific articles. He has also served as a reviewer for various scientific journals, and is a member of the Research Society on Alcoholism, and an Associate Fellow of the Aerospace Medical Association.